Supported by an educational grant from LEO Pharma
Recognize the epidemiology of Hidradenitis Suppurativa
Recognize primary lesions at early stage of disease
Implement early diagnosis to prevent morbidity and provide effective treatment outcomes
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Joseph Gorelick, MSN, FNP-C has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: AbbVie Pharmaceuticals, Dermira, Lilly, LEO Pharma, Novartis Pharmaceuticals, Ortho Dermatologics, Pfizer, PruGen, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharma, and UCB. Advisory Board/Speaker’s Bureau: AbbVie Pharmaceuticals, Dermira, Lilly, LEO Pharma; Novartis Pharmaceuticals, Ortho Dermatologics, Pfizer, PruGen, Regeneron Pharmaceuticals, Sun Pharma, and UCB.
Accreditation and Medical Education Support Disclosure
Susan Gallagher-Pecha and Erin Fletcher of Evolve Medical Education LLC have no real or apparent conflicts of interest to report.
Stacey Moore of Physician Resources, LLC has no real or apparent conflicts of interest to report.